Your session is about to expire
← Back to Search
Monoclonal Antibodies
ANX005 for Autoimmune Hemolytic Anemia
Phase 2
Waitlist Available
Led By Morie Gertz, MD
Research Sponsored by Annexon, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to day 71
Awards & highlights
No Placebo-Only Group
Summary
This trial will test the safety of ANX005, an IV treatment, in people with Warm Autoimmune Hemolytic Anemia. The treatment aims to stop the immune system from attacking red blood cells.
Eligible Conditions
- Autoimmune Hemolytic Anemia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to day 71
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to day 71
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in disease activity biomarkers
Safety: Treatment-emergent adverse events (TEAEs)
Secondary study objectives
Change in complement system biomarkers
Plasma concentrations
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: ANX005Experimental Treatment1 Intervention
Participants will receive two once-weekly doses of ANX005 at specific time points
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ANX005
2021
Completed Phase 3
~310
Find a Location
Who is running the clinical trial?
Annexon, Inc.Lead Sponsor
13 Previous Clinical Trials
1,473 Total Patients Enrolled
Study DirectorStudy DirectorAnnexon, Inc.
1,278 Previous Clinical Trials
499,648 Total Patients Enrolled
Morie Gertz, MDPrincipal InvestigatorMayo Clinic, Rochester, MN
Share this study with friends
Copy Link
Messenger